Epidermal Growth Factor Receptor Mutation Status: Does Younger Mean More Frequently Mutated?

Affiliations

¹ Oncogene Diagnostics LLC, 31-546 Kraków, Poland.
² Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-950 Lublin, Poland.
³ National Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
⁴ Genetics and Immunology Laboratory Genim LLC, 20-609 Lublin, Poland.
⁵ Department of Pathology, Lower Silesian Center of Lung Diseases, 53-439 Wroclaw, Poland.
⁶ Department of Pathology, Pulmonary Hospital, 34-500 Zakopane, Poland.
⁷ Oncology Department, John Paul II Hospital, 31-202 Kraków, Poland.
⁸ Department of Clinical Oncology, Poznan University of Medical Science, 61-701 Poznan, Poland.
⁹ Department of Thoracic Surgery and Transplantation, Pomeranian Medical University, 70-204 Szczecin Zdunowo, Poland.
¹⁰ Department of Bioinformatics and Telemedicine, Jagiellonian University Medical College, 31-007 Kraków, Poland.

Wójcik P et al. Balkan J Med Genet. 2017.

. 2017 Dec 29;20(2):89-90.

doi: 10.1515/bjmg-2017-0029. eCollection 2017 Dec.

¹ Oncogene Diagnostics LLC, 31-546 Kraków, Poland.
² Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-950 Lublin, Poland.
³ National Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
⁴ Genetics and Immunology Laboratory Genim LLC, 20-609 Lublin, Poland.
⁵ Department of Pathology, Lower Silesian Center of Lung Diseases, 53-439 Wroclaw, Poland.
⁶ Department of Pathology, Pulmonary Hospital, 34-500 Zakopane, Poland.
⁷ Oncology Department, John Paul II Hospital, 31-202 Kraków, Poland.
⁸ Department of Clinical Oncology, Poznan University of Medical Science, 61-701 Poznan, Poland.
⁹ Department of Thoracic Surgery and Transplantation, Pomeranian Medical University, 70-204 Szczecin Zdunowo, Poland.
¹⁰ Department of Bioinformatics and Telemedicine, Jagiellonian University Medical College, 31-007 Kraków, Poland.

No abstract available

Figures

1. Mok T, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. - PubMed
1. Nagashima O, Ohashi R, Yoshioka Y, Inagaki A, Tajima M, Koinuma Y. et al. High prevalence of gene abnormalities in young patients with lung cancer. J Thorac Dis. 2013;5(1):27–30. - PMC - PubMed
1. Van den Bussche CJ, Illei PB, Lin MT, Ettinger DS, Maleki Z.. Molecular alterations in non-small cell lung carcinoma of the young. Hum Pathol. 2014;45(12):2379–2387. - PubMed
1. Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR.. Lung cancer diagnosed in the young is associated with enrichment for targetable genomic alterations and poor prognosis. JAMA Oncol. 2016;2(3):313–320. - PMC - PubMed
1. Nishi T, Yokose T, Miyagi Y, Daigo Y, Ito H, Isaka T. et al. Clinicopathological features and EGFR gene mutation status in elderly patients with resected nonsmall-cell lung cancer. BMC Cancer. 2014;14:610. doi: 10.1186/1471-2407-14-610. - DOI - PMC - PubMed